Subscribe to Search results

When Dr Mitchell arrived at the Sheffield Centre, the majority of patients on home treatment were receiving commercial concentrate and he did not have the ability to switch them all over to NHS concentrates given the amount received.

Published on:

Whilst there were insufficient supplies so commercial concentrates were used. Dr Mitchell would have used more NHS product if it had been available.

Published on:

The approach at the Sheffield Centre for adults with severe Haemophilia A, was to treat them with NHS concentrates as much as possible.

Published on:

Local meetings with the Inquiry team

Published on:

Dr Mitchell did not experience difficulties with obtaining sufficient quantities of cryoprecipitate or with adverse reactions to cryoprecipitate.

Published on:

Dr Mitchell acknowledged that reactions could occur but did he not recall it being a major problem.

Published on:

Children with severe haemophilia, were to be treated with cryoprecipitate by the Sheffield Centre until they went onto home treatment.

Published on:

Dr Mitchell used DDAVP and tranexamic acid wherever possible for mild and moderate haemophilia and for von Willebrand disorder. This was largely successfully, although it was not always adequate for moderate patients.

Published on:

Dr Mitchell believed there to be a connection between the use of multi-donor factor concentrates and the development of liver disease.

Published on:

Dr Mitchell understood from the 1978 Sheffield study in some patients liver disease was significant and progressive. He decided to restrict the use of large donor pool concentrates whenever possible in order to liver disease.

Published on:

Dr Mitchell argued "recurrent treatment with blood products is hazardous... The best approach seems to us to be a treatment policy" designed to reduce all the risks associated with blood products and is tailored to the needs of individual patients.

Published on:

Haemophilia B was referred to "Christmas disease" after the name of the first patient whose condition was examined in detail.

Published on:

Prior to 1952 patients were categorised under a generic diagnosis of haemophilia, but by 1952 Haemophilia B could be identified separately from Haemophilia A.

Published on:

It was stated that the "The biological roles of Factors 8 and 9 are closely related...and so the clinical picture that is caused by these deficiencies is near identical."

Published on:

An application for renewal of product licence Proplex Factor IX Complex was made from Travenol Laboratories

Published on:

Proplex Factor IX Complex (Human) was granted a product licence

Published on:

Authority was given for the grant of a product licence for Proplex Factor IX Complex

Published on:

Table provided Protein Fraction Centre licences updates and renewals

Published on:

Part II Licensing granted authority for products including 'dried human antihemophilic fraction' and 'dried human factor IX fraction'

Published on:

As the 1970s progressed, home therapy with Factor 9 concentrates became a feature of the treatment of people with Haemophilia B

Published on: